BioPharmSignal logoBioPharmSignal

Biotech News

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Biotherapeutics (ARQT)Arcutis BiotherapeuticsCommercial

WESTLAKE VILLAGE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 143,500 restricted stock units

Related news

ARQTArcutis Biotherapeutics2026-07-16 13:00 EST

Arcutis Expands Board of Directors with Appointment of Chris Peetz

ARQTArcutis Biotherapeutics2026-03-05 14:00 EST

Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth

View all latest news

Arcutis Biotherapeutics

Medical Dermatology Arcutis Biotherapeutics develops and commercializes targeted therapies for immune-mediated skin diseases, emphasizing convenient topical formulations against validated biology. ZORYVE Franchise ZORYVE is a once-daily topical roflumilast product available in cream and foam formulations across plaque psoriasis, atopic...

Recent company news

ARQTArcutis Biotherapeutics2026-08-07 20:00 EST

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ARQTArcutis Biotherapeutics2026-08-05 20:00 EST

Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update

ARQTArcutis Biotherapeutics2026-07-16 13:00 EST

Arcutis Expands Board of Directors with Appointment of Chris Peetz

ARQTArcutis Biotherapeutics2026-07-15 20:00 EST

Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026

ARQTArcutis Biotherapeutics2026-07-08 12:00 EST

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

Stock data

Close
26.43 USD
Market cap
2.6B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States